Pharma BD Deal Intelligence
Sanofi-Synthelabo launched a 48.5 billion-euro hostile takeover bid for Aventis (successor to Rhone-Poulenc) in a daring move to create the third-largest drugs…
Analysts said it was only a matter of time, and price, before Aventis agrees to become part of Sanofi, framing the contested bid as a question of valuation…
Sanofi-Synthelabo and Aventis agreed a friendly merger creating Sanofi-Aventis, the largest pharmaceuticals group in Europe and third largest worldwide, after…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Sanofi and Rhone-Poulenc are connected through corporate lineage rather than a direct acquisition between the two. Rhone-Poulenc merged with Hoechst in 1999 to form Aventis; in 2004, Sanofi-Synthelabo acquired Aventis -- initially through a hostile bid valued at roughly EUR 48.5 billion and ultimately agreed as a friendly merger -- to create Sanofi-Aventis, then the world's third-largest pharmaceutical group. No standalone transaction in which Sanofi acquired Rhone-Poulenc took place.
$46B Sanofi Revenue (2024)
Rhone-Poulenc was founded in 1895 through the merger of Societe Chimique des Usines du Rhone and Etablissements Poulenc Freres. The combined entity became France's largest chemical and pharmaceutical company, producing dyes, synthetic fibers, agrochemicals, and drugs. The company played a key role in developing sulfonamide antibiotics and chlorpromazine (the first antipsychotic).
Rhone-Poulenc's history spans the full arc of French industrial chemistry. Its pharmaceutical division developed chlorpromazine in 1950, revolutionizing psychiatry. The company merged with Hoechst in 1999 to form Aventis, which Sanofi acquired in 2004. This lineage makes Sanofi's pharmaceutical heritage one of the most complex in the industry, blending French and German chemical traditions.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Rhône-Poulenc (this deal) | 1895 | — | 48 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 1895 deals · Sanofi SA deals · Neurology deals